Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11576356

Genetically modified non-human animals and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11571636

Methods for quantitating individual antibodies from a mixture

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11571482

Human antibodies to S. aureus Hemolysin A toxin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559564

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559489

Tuning of release kinetics in hydrogels

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559576

Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11548947

Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11548932

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11547101

Non-human animals having a disruption in a C9ORF72 locus

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11542326

Anti-IL-25 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11542317

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11535675

Antigen-binding proteins that antagonize leptin receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11535663

Methods for producing aflibercept in chemically defined media having reduced aflibercept v

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11530255

Human antibodies to Ebola virus glycoprotein

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11525001

Anti-CD8 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11525629

Target residual moisture content for lyophilized drug product

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11519020

Methods of associating genetic variants with a clinical outcome in patients suffering from

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11518804

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11512309

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11511001

Radiolabeled anti-LAG3 antibodies for immuno-PET imaging

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11505593

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11504390

Treatment of increased lipid levels with sterol regulatory element binding transcription f

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11504426

Methods for treating allergy and enhancing allergen-specific immunotherapy by administerin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11505594

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted